報價延遲最少15分鐘:2024/05/17 02:22 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
1.965 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-1.87/-1.47
|
|
企業價值
22.98M
|
| 資產負債 |
|
每股賬面淨值
2.59
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2024/05/17 02:22 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first- and-in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). |